According to an NBC News report, the Institute for Clinical and Economic Review (ICER), an independent, non-profit organization that analyzes clinical and cost effectiveness in new medicines, has taken issue with the price of two recently approved cholesterol drugs. The medications, which belong to a new class of cholesterol drugs called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, are Sanofi and Regeneron’s Praluent and Amgen’s Repatha. ...
Review Group Says New Cholesterol Drugs Too Expensive
Posted October 4, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
Study Suggests Statin Use May Increase Risk of Cataracts
Posted October 3, 2013 in Product News and Recalls
A new study has emerged that links statin medication to the risk of developing cataracts, according to US News and World Report.
Researchers with the VA North Texas Health System published study results in the online edition of JAMA Ophthalmology, in which they analyzed data from over 14,000 statin users. They found that statin users had a 27% greater risk of developing cataracts. Even after analyzing the data several different ways, the same association emerged: statin use was ...
continue reading...Health warnings issued for cholesterol drugs
Posted September 23, 2013 in Drug and Medical Device Lawsuits | Health | Legal Issues | Lipitor | Product Liability | Product News and Recalls
In a study published in Annals of Internal Medicine, Canadian researchers are advising doctors to avoid ordering certain antibiotics for patients taking the cholesterol-lowering drugs known as statins, which include Lipitor.
An article in U.S. News and World Report says statins don’t mix well with the antibiotics clarithromycin or erythromycin.
This isn’t the first time that health concerns have been raised about statins. The U.S. Food and Drug Administration has added warnings ...
continue reading...When is the last time you went to watch your favorite television show or listen to your favorite radio program and you were able to do so without being exposed to an advertisement from a pharmaceutical company? It feels like almost every day we are introduced to a new drug that claims to improve our lives. It is true that modern medicine can greatly improve our quality of life, but all drugs carry risks, and the risks are often minimized ...
continue reading...Diet changes an option for Lipitor users
Posted July 31, 2013 in Health | Legal Issues | Lipitor | Product Liability | Product News and Recalls
An ABC News report asks the question of whether America is an “overmedicated nation,” and offers alternatives to some of the most commonly prescribed medications.
Among those medications are the anti-cholesterol drugs known as statins. According to the report, the pharmacies fill more than 45 million prescriptions a year for the statin known as Lipitor alone.
But recent research indicates that statins may carry some health risks. The U.S. Food and Drug ...
continue reading...
A story in the Irish Independent says Pfizer intends to sell one of its Irish plants, in large part because of declining revenues from its anti-cholesterol drug Lipitor.
Sales of Lipitor, a former blockbuster for the company, have been plummeting recently because its patent expired, opening it up to competition from generics. The drug has also been the subject of some recent health concerns.
The U.S. Food and Drug Administration has added ...
continue reading...
